| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | -0.0008 | 1 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.00083 | 1 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.00081 | 1 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | -0.00099 | 1 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.00065 | 1 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.00092 | 1 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | -0.0006 | 1 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.00083 | 1 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.00092 | 1 |